LIPUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.75 SEK | +1.74% |
|
+9.38% | +34.20% |
| 06-18 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
| 05-28 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2023 | - | Sales 2024 * | - | Capitalization | 186M 1.95B 14.68B |
|---|---|---|---|---|---|
| Net income 2023 | -37M -389M -2.93B | Net income 2024 * | -41M -431M -3.24B | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | 54.3 570.25 4.29K | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 5 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 44.85% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.74% | ||
| 1 week | +9.38% | ||
| Current month | +27.74% | ||
| 1 month | +40.00% | ||
| 3 months | +27.92% | ||
| 6 months | +26.81% | ||
| Current year | +34.20% |
1 week
8.00
11.00
1 month
6.1511.00
Current year
5.5011.00
1 year
5.5015.00
3 years
5.5027.45
5 years
5.5028.97
10 years
5.5028.97
| Managers | Title | Age | Since |
|---|---|---|---|
Ola Sandborgh
CEO | Chief Executive Officer | - | 11-30 |
| Founder | 64 | 16/06/10 | |
| Founder | 79 | 16/06/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 31/12/20 | |
Carl-Johan Spak
BRD | Director/Board Member | 68 | 31/12/22 |
| Director/Board Member | - | 31/12/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 8.75 | +1.74% | 14,838 |
| 19/06/24 | 8.6 | +3.61% | 7,232 |
| 18/06/24 | 8.3 | +3.75% | 19,646 |
| 17/06/24 | 8 | 0.00% | 74 |
| 14/06/24 | 8 | -2.44% | 6,228 |
Delayed Quote Nasdaq Stockholm, June 20, 2024 at 05:00 pm
More quotes
Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.20% | 17.61M | |
| +2.22% | 93.91B | |
| -1.32% | 38.4B | |
| -13.44% | 32.61B | |
| +76.30% | 28.2B | |
| -13.11% | 15.91B | |
| +0.68% | 14.22B | |
| -12.06% | 11.54B | |
| +185.28% | 10.74B | |
| -53.00% | 9.47B |
- Stock Market
- Equities
- LIPUM Stock
